Todas las investigaciones
CompletadoFase IIIntervencionista

GuARD - GR1014 cutaneous gel Against Radiation Dermatitis

Radiotherapy is an important treatment after breast cancer surgery because it lowers the chance of cancer returning. However, it often irritates the skin on the treated breast, causing sunburn-like redness, peeling, swelling, and soreness. This is called radiation dermatitis. This trial is testing a new skin gel named GR1014. The gel is designed to protect healthy skin cells from radiation damage without stopping the cancer treatment from doing its job. Women taking part will receive either a standard harmless base gel (a placebo) or one of two strengths of the active gel. The study will look at how well the gel protects the skin, how gentle it is, and whether it causes any unwanted side effects. It aims to make radiotherapy more comfortable for women recovering from breast cancer surgery.

De un vistazo

Estado
Completado
Fase
Fase II
Patrocinador
Graegis Pharmaceuticals Ltd
Objetivo de inscripción
273
Inicio
26 Jul 2024
Estimación de finalización
11 Apr 2025

¿De qué trata este estudio?

Many women diagnosed with early-stage breast cancer have surgery called a lumpectomy to remove the lump while keeping the rest of the breast. After surgery, doctors usually recommend radiotherapy. This uses targeted radiation beams to destroy any tiny cancer cells that might be left behind. Radiotherapy is very effective, but it often causes skin reactions similar to sunburn. The skin can become very red, itchy, swollen, sore, and sometimes peel.

Doctors are looking for better ways to protect the skin during treatment so patients feel more comfortable. This study is testing an experimental skin gel called GR1014. The active ingredient is thought to shield healthy skin cells from radiation damage. Importantly, research suggests the gel protects only the surface skin and does not stop the radiotherapy from killing cancer cells deeper inside the tissue.

In this Phase II trial, researchers want to see if applying this gel directly to the breast can reduce or completely prevent skin soreness. They also need to check that the gel is safe and does not cause problems of its own. If successful, this gel could become a useful new option to help women complete their cancer treatment with fewer painful skin side effects.

Puntos clave

  • The trial tests a protective gel (GR1014) to prevent skin redness and soreness during radiotherapy.
  • It is for women having radiotherapy after lumpectomy for early breast cancer.
  • Participants will receive either one of two strengths of the gel or a dummy gel (placebo).
  • The gel is designed to protect your skin without reducing how well radiotherapy treats the cancer.
  • Participation is entirely voluntary and will not disrupt your planned radiotherapy schedule.

¿Quién puede ser elegible?

This trial is for women aged 18 and older who have had breast-conserving surgery (a lumpectomy) for early-stage breast cancer that has not spread to other parts of the body. Participants must have fully recovered from their surgery and any chemotherapy before joining. They must also be scheduled to have a short, five-day course of radiotherapy to the whole breast.

To take part, your skin in the treatment area must currently be healthy, with no existing irritation or rashes. If you could become pregnant, you will need to take a pregnancy test and agree to use very reliable contraception during the trial and for a month afterwards.

Because of local study requirements, participants must be covered by the French healthcare system (Social Security) and be well enough to manage daily activities and attend all clinic appointments.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. You are a woman aged 18 or older.
  2. You have had lumpectomy surgery for early breast cancer that has not spread.
  3. You have finished healing from surgery and chemotherapy.
  4. You are scheduled for a 5-day course of whole-breast radiotherapy.
  5. The skin on your treated breast is currently clear of any rash or sores.
  6. You are covered by the French healthcare system (Social Security).
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you join the study, you will be put into one of three groups by chance (like flipping a coin). One group will use a gel with no active medicine (a dummy gel or 'placebo'), while the other two groups will use the gel with either a lower or higher strength of the active ingredient. Neither you nor your doctors will know which gel you receive until the trial ends.

You will apply the gel to your breast as instructed around the time of your planned radiotherapy sessions, which run across five appointments. During your visits, the research team will check your skin closely to see how it reacts. They will also take routine safety checks, such as measuring your blood pressure, checking your heart rate, and taking blood samples to test your calcium levels and see how your body processes the gel.

The overall study runs over several months to allow doctors to monitor how your skin heals and check on your general wellbeing after radiotherapy ends.

Riesgos y beneficios potenciales

Taking part may help protect your skin from the soreness, peeling, and redness often caused by radiotherapy, though this cannot be guaranteed. You will also be helping doctors find better ways to care for future breast cancer patients. Like all treatments, the gel carries potential risks. It might cause temporary skin irritation, redness, itching, or mild swelling. Very rarely, an allergic reaction could occur. The study uses low doses to keep these risks small and prevent medicine from entering your bloodstream. Your care team will watch you closely throughout the trial. Joining is entirely your choice, and you can change your mind and leave the study at any time without it affecting your cancer treatment.

Ubicaciones (4)

  • The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research
    Solo ciudad
    Sutton, England
  • Institut Gustave Roussy
    Approximate
    Villejuif, Francia
  • Centre Léon Bérard
    Approximate
    Lyon, Francia
  • Institut Bergonié
    Approximate
    Burdeos, Francia

Preguntas comunes

Will using this gel stop my radiotherapy from working?

No. Tests show that the gel only works on the surface of the skin and does not stop the radiation beams from destroying cancer cells in the breast.

What is a placebo gel?

A placebo gel looks and feels identical to the active gel, but it contains no medicine. Comparing the active gel against a placebo helps researchers clearly see if the treatment works.

Do I have to change my radiotherapy plan to take part?

No. The trial works alongside your standard planned radiotherapy sessions, so your main cancer treatment will go ahead as scheduled.

Can I leave the study if I get uncomfortable?

Yes. Taking part is completely voluntary. You are free to stop using the gel at any point, and your standard cancer care will continue as normal.

Will taking part cost me anything?

No. The study gel and any extra tests or visits related to the trial are provided free of charge by the study sponsor.

Cómo obtener más información

Valérie Ferrand

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.